Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

35.21 +0.48 (+1.38%)
Streaming Delayed Price Updated: 2:55 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Travere Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why ↗
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug. 
Via Investor's Business Daily
Topics Government
News headline image
Top movers in Friday's pre-market session ↗
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries ↗
Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth? ↗
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX). 
Via Chartmill
News headline image
Travere Therapeutics Reports First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Assessing Travere Therapeutics: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval ↗
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
News headline image
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts ↗
 
Via Benzinga
News headline image
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.